Huons Co. Ltd (243070) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Huons Co. Ltd (243070) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩10.92 Billion ≈ $7.40 Million USD) by net assets (₩395.25 Billion ≈ $267.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Huons Co. Ltd for the company's overall valuation and market capitalisation.
Huons Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Huons Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Huons Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Huons Co. Ltd ranked by their cash flow conversion efficiency. Explore Huons Co. Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kolon Globalco
KO:003070
|
-0.145x |
|
Amaero Ltd
AU:3DA
|
-0.190x |
|
Digital Daesung Co. Ltd
KQ:068930
|
0.099x |
|
Acme United Corporation
NYSE MKT:ACU
|
-0.019x |
|
Silver Mountain Resources Inc
V:AGMR
|
-0.044x |
|
Airtel Africa Plc
LSE:AAF
|
0.286x |
|
PIE Industrial Bhd
KLSE:7095
|
0.036x |
|
Paragon Care Ltd
AU:PGC
|
-0.088x |
Annual Cash Flow Conversion Efficiency for Huons Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Huons Co. Ltd from 2016 to 2024. View Huons Co. Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩345.97 Billion ≈ $234.46 Million |
₩52.56 Billion ≈ $35.62 Million |
0.152x | -3.74% |
| 2023-12-31 | ₩330.41 Billion ≈ $223.92 Million |
₩52.14 Billion ≈ $35.34 Million |
0.158x | +39.22% |
| 2022-12-31 | ₩282.46 Billion ≈ $191.42 Million |
₩32.02 Billion ≈ $21.70 Million |
0.113x | -45.74% |
| 2021-12-31 | ₩266.09 Billion ≈ $180.33 Million |
₩55.59 Billion ≈ $37.67 Million |
0.209x | +7.28% |
| 2020-12-31 | ₩238.80 Billion ≈ $161.83 Million |
₩46.51 Billion ≈ $31.52 Million |
0.195x | -10.06% |
| 2019-12-31 | ₩194.52 Billion ≈ $131.82 Million |
₩42.12 Billion ≈ $28.54 Million |
0.217x | +69.29% |
| 2018-12-31 | ₩163.27 Billion ≈ $110.64 Million |
₩20.88 Billion ≈ $14.15 Million |
0.128x | -48.05% |
| 2017-12-31 | ₩122.69 Billion ≈ $83.15 Million |
₩30.21 Billion ≈ $20.47 Million |
0.246x | -46.72% |
| 2016-12-31 | ₩93.88 Billion ≈ $63.62 Million |
₩43.38 Billion ≈ $29.40 Million |
0.462x | -- |
About Huons Co. Ltd
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other ch… Read more